Therapeutic approaches in inflammatory bowel disease (IBD) involve targetin
g the broad inflammatory process, targeting specific inflammatory mediators
, changing the interior milieu to diminish antigenic drive, or removing the
main mediators of inflammation, the inflammatory cells, completely. Recent
developments have occurred in each of these therapeutic areas. New steroid
s, and better use of existing drugs, such as azathioprine and cyclosporin,
have improved therapy. Genetically engineered drugs, such as TNF-alpha anti
body, offer the prospect of powerful treatment for patients resistant to st
andard therapies. The use of probiotics offers an entirely new approach, by
changing the lumenal milieu. Understanding how bacteria and epithelial cel
ls interact is likely to bring important rewards in therapy. Finally, immun
e cell replacement may be a possible therapy for severe disease when all el
se has failed.